Financings

Allon Therapeutics Inc. closed a $10 million venture financing.

AVEO Pharmaceuticals Inc. is raising $61 million in a private placement of stock.

Coronado Biosciences Inc. raised $21.6 million in a series of private financings.

Dynavax Technologies Corp. raised $44.97 million in its previously announced public stock offering.

Karyopharm Therapeutics Inc. raised $20 million in a Series A financing.

Med BioGene Inc. has been unable to complete its proposed Nasdaq initial public offering.

Oncolytics Biotech Inc. is raising $24.5 million in a bought deal financing of stock and warrants.

Pacira Pharmaceuticals Inc. filed to raise up to $86.25 million in an initial public offering.

PharmAthene Inc. raised $14.1 million in a public stock offering.

Zealand Pharma A/S is aiming to raise $126.1 million in a Danish initial public offering.

Deals

Amicus Therapeutics Inc. signed a $230 million deal with GlaxoSmithKline plc for Fabry disease drug Amigal.

Insys Therapeutics Inc. is going public via a reverse merger with NeoPharm Inc.

Kadmon Pharmaceuticals LLC licensed certain rights to taribavirin and ribavirin from Valeant Pharmaceuticals International Inc.

Maxygen Inc. sold its MolecularBreeding platform technology to Codexis Inc. for $20 million in cash.

. . . And More

BioWorld Today has coverage of the American Association for the Study of Liver Diseases annual meeting.

Avanir Pharmaceuticals Inc. won FDA approval of Nuedexta for pseudobulbar affect.

Biodel Inc. got a complete response letter for diabetes drug Linjeta (human insulin [rDNA origin]).

Biogen Idec Inc. is cutting 650 full-time jobs and focusing on neurological diseases.

Cadence Pharmaceuticals Inc. won FDA approval of Ofirmev (I.V. acetaminophen) for pain and fever.

Forest Laboratories Inc. won FDA approval of antibiotic Teflaro (ceftaroline fosamil).

Ironwood Pharmaceuticals Inc. got more good Phase III data with linaclotide.

VaxGen Inc. has been renamed diaDexus Inc. following the firms' reverse merger.